AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

AnaptysBio (ANAB) stock market value increased 16.42% since last Buy rating. Financial partnership with GSK bodes favorably with hopes for added growth. Read more here.

AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ‘highest ever’ responses at week 14, with 69% of patients achieving ...

Ratings for AnaptysBio (NASDAQ:ANAB) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.Summarizing their recent assessments, the table ...

AnaptysBio, Inc. (NASDAQ:ANAB) is a clinical-stage biotechnology company, focusing on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology.

What happenedShares of clinical-stage biotech AnaptysBio (NASDAQ: ANAB) were rising sharply on Tuesday following bullish commentary from a Wall Street analyst. The company's stock was up by 5.6% ...

AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AnaptysBio, Inc. (ANAB) shares rallied 30.5% in the last trading session to close at $16.15. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

TD Cowen analyst Joseph Thome has maintained their bullish stance on ANAB stock, giving a Buy rating today. Joseph Thome’s rating is based on several compelling factors. Despite AnaptysBio ...

Oct 9 (Reuters) - AnaptysBio Inc (ANAB.O), opens new tab said on Monday its experimental drug to treat a type of rare skin disease met the main goal in a late-stage study. The drug helped in ...